Literature DB >> 12843825

[Assessment off-label prescribing in Dermatology].

D Picard1, P Carvalho, C Bonnavia, L Louin, V Josset, Ph Lauret, P Joly.   

Abstract

INTRODUCTION: The official policy of the French National Health Insurance system is to deny reimbursement for drugs prescribed for off-label indications. The objectives of this study were 1) to quantify the use of off-label prescriptions by physicians from a hospital department of dermatology in France; 2) to characterize these off-label prescriptions; 3) to assess data from the literature on the appropriateness of these off-label prescriptions. PATIENTS AND METHODS: For each patient consulting between February 1 and April 1, 2001, the symptom or the disease that was treated and the type of prescription were recorded on standard forms.
RESULTS: Eighty six percent of prescriptions were labelled, 14 p. 100 were off-labelled. Inflammatory and hypersensitivity dermatoses were the most frequent indications of off-label prescriptions (26 p. 100). Treatments which most frequently corresponded to off-label prescriptions were topical corticosteroids and methotrexate. Examination of the literature showed that 70 p. 100 of the off-label prescriptions were not based on strong data from evidence-based-medicine. Many off-label prescriptions were made by the most graduate physicians. DISCUSSION: This study showed a great number of off-label prescriptions in dermatology. These prescriptions were often related to rare diseases that were managed by senior dermatologists. These off-label prescriptions were rarely in accordance with data from evidence-based-medicine.

Entities:  

Mesh:

Year:  2003        PMID: 12843825

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  3 in total

1.  [Off-label use in dermatological practice. The conflict between professional duty and legal requirements].

Authors:  V Brunne; G Mertins; G Reimann; N H Brockmeyer
Journal:  Hautarzt       Date:  2004-08       Impact factor: 0.751

2.  [Appropriate off-label prescription in practice].

Authors:  M Augustin
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

3.  [Approved systemic therapies in dermatology].

Authors:  Monika Kleinhans; Carolin Funke-Lorenz; Joachim Dissemond
Journal:  Hautarzt       Date:  2021-04-21       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.